Diabetes drug repurposed in fight against childhood cancers
NCT ID NCT05521984
Summary
This early-stage study is testing whether adding the diabetes medication dapagliflozin to standard cancer treatments is safe for children and young adults with recurrent brain tumors or solid tumors that have not responded to previous therapies. Researchers want to see if the drug can help shrink tumors by altering how cancer cells use energy. The study will enroll up to 20 participants aged 6 to 21 who have no other curative options available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC BRAIN TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine/St. Louis Children's Hospital
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.